Cyril Amarchand Mangaldas advised Biocon Limited (Biocon), in relation to the sale of shares by Biocon Limited in Syngene International Limited (Syngene International), by way of a bulk trade on the stock exchanges, aggregating to INR 1220.28 crores.
The Capital Market Practice of Cyril Amarchand Mangaldas advised Biocon for the transaction and assisted with, reviewing, and finalizing the transaction documents. The transaction team was led by Reuben Chacko, Partner; Janhavi Manohar, Partner; with support from Tanvi Kini, Senior Associate.
Other Parties and Advisors to the transaction included Spark Capital Advisors (India) Private Limited and Avendus Capital Private Limited (Broker and Advisor, respectively); Linklaters Singapore Pte (U.S. federal securities law counsel to Broker and Advisor).
The transaction was signed on September 05, 2022; and closing on September 08, 2022.
About Cyril Amarchand Mangaldas
Cyril Amarchand Mangaldas (cam) is India’s leading law firm with a global reputation of being trusted advisers to its clients. The Firm advises a large and diverse set of clients, including domestic and foreign commercial enterprises, financial institutions, private equity and venture capital funds, start-ups, government and regulatory bodies. The Firm generalists, specialists and senior ex-regulators expertly guide clients across a spectrum of transactions, sectors and regulations. With 1000 lawyers and 160 Partners, the Firm is the largest full-service law firm in India and offices in key business centres at Mumbai, Delhi-NCR, Bengaluru, Ahmedabad, Hyderabad, Chennai, GIFT City and also in Singapore.
The Firm recently received “Innovation in Advancing Markets” award at the FT Innovative Lawyers Asia Pacific 2022 Awards and the “National Law Firm of the Year: India” award at the IFLR Asia Pacific 2022 awards ceremony. The Firm had won “India Deal Firm of the Year” at the ALB India Awards and “Firm of the Year” at the IFLR1000 India Awards in 2021.
